28Aug 2024
Risk of Herpes Zoster Elevated in RA Patients on Tofacitinib with Recent bDMARDs Use

Risk of Herpes Zoster Elevated in RA Patients on Tofacitinib with Recent bDMARDs Use

Results from a study on rheumatoid arthritis (RA) patients treated with tofacitinib (TOFA) indicated a higher incidence of herpes zoster (HZ) among those with recent biologic synthetic disease-modifying anti-rheumatic drugs (bDMARDs) use. Of 304 RA patients, 97 had recent bDMARDs use, and 207 did not. The overall HZ incidence rate was 5.62 per 100 person-years, with patients in the recent bDMARDs group having a significantly higher HZ risk (incidence rate ratio: 2.34, 95% CI: 1.04–5.19, p = 0.028). Multivariable analysis confirmed recent bDMARDs use (hazard ratio: 2.4, 95% CI: 1.12–4.95, p = 0.024) as an independent risk factor for HZ. Kaplan-Meier analysis corroborated increased HZ risk in patients with recent bDMARDs use (log-rank p = 0.015). These findings suggest that HZ vaccination should be considered for RA patients on TOFA, especially those with recent bDMARDs us

  • #rheumatology

Like

Save

Share